Details for United Kingdom Supplementary Protection Certificate: SPC/GB06/025

✉ Email this page to a colleague

United Kingdom Supplementary Protection Certificate: SPC/GB06/025

These international patent data are derived from patent families, based on US drug-patent linkages. Accordingly, they should not be regarded as comprehensive records of ex-US drug-patent associations.

Glossary

Subscribe to access the full database, or Sign Up
Country	Patent Number	Supplementary Protection Certificate	SPC Country	SPC Description	SPC Expiration
European Patent Office	0804237	SPC/GB06/025	United Kingdom	PRODUCT NAME: NATALIZUMAB, ANTI -4 INTEGRIN HUMANIZED MONOCLONAL ANTIBODY; REGISTERED: UK EU/1/06/346/001 20060627	⤷ Sign Up
>Country	>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Description	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.